As a quadruple board-certified physician and a patient with a complex autoimmune disease, I live on both sides of the examination table. My professional life is about finding answers; my personal life has been about the agony of waiting for them.

This dual perspective makes it impossible to ignore a systemic problem in modern medicine: A class of diagnoses that live in the shadows. Seronegative Sjögren’s, mast cell activation syndrome (MCAS), dysautonomia, chronic fatigue (ME/CFS), and small fiber neuropathy (SFN) are the ghosts in our machine. They cross every specialty, refuse to conform to our tidy flowcharts, and leave a trail of frustrated patients and deeply uncomfortable physicians in their wake.

They haunt our patients. Let’s be honest with ourselves—they haunt us, too.

The ghosts in every specialty

• For the rheumatologist, it’s seronegative Sjögren’s. The patient’s story screams autoimmunity—debilitating fatigue, sicca, systemic pain—but their labs are silent. With 30 to 40 percent of Sjögren’s patients being seronegative, we are left to weigh a clinical diagnosis against the “gold standard” of a lip biopsy, asking a patient to risk permanent numbness for a label we feel in our bones is correct.
• For the allergist, it’s the tightrope of MCAS. We’re caught between the rigid Consensus 1 criteria, which demand a fleeting tryptase spike that’s nearly impossible to capture, and the more clinical Consensus 2. We are terrified of both over-diagnosing a nebulous condition and under-diagnosing the patient whose life has shrunk to four foods and four walls.
• For the neurologist, it’s the conundrum of SFN and dysautonomia. We are masters of the reflex hammer, yet these conditions live in the invisible wires of the small fiber and autonomic nerves. We are forced to rely on a patient’s subjective story while the “objective” tests—a skin punch biopsy, a tilt table, a QSART—are difficult to get and not always definitive.
• For all of us, it’s the diagnostic orphan of ME/CFS. This is the condition that perhaps has no single specialty home, leaving it to the brave internist, neurologist, or rheumatologist willing to take it on. Its hallmark is post-exertional malaise (PEM)—a pathological inability to produce energy on demand, where a simple trip to the grocery store can cause a multi-day “crash” of profound flu-like symptoms and fatigue.

My tightrope walk: The fears we don’t say out loud

In the face of these ghosts, my role as a steady, all-knowing physician feels like a tightrope walk over a canyon of uncertainty. And as a patient, I know how far the fall is. These are the fears that wake me up in the middle of the night:

• I’m afraid of missing it. My training, my intuition, and the patient’s story all point to a “perfect storm” of illness. But without that positive antibody test—the so-called “proof”—I’m afraid of delaying a diagnosis that could prevent irreversible damage. I’m afraid of unintentionally gaslighting my own clinical judgment, let alone my patient.
• I’m afraid of the system failing my patient. I know what’s coming: The battle with insurance, the skepticism from colleagues, the endless hoops. It’s a core reason I built a direct care practice—to rebel against a system that requires a black-and-white data point for a gray-scale human. My fear is that despite my best efforts, the system will still slam the door on them.
• I’m afraid of causing “diagnostic fatigue.” The journey to an answer can be as traumatic as the illness itself. I’m afraid of ordering that next invasive test. Am I pushing my patient towards a procedure with real risks just to get a label that will satisfy a bureaucratic need for certainty? The burden of that proof feels incredibly heavy.
• And my biggest fear? I’m afraid of the patient giving up. That the person in front of me, exhausted and invalidated, will lose all hope.

The anatomy of our fear

This fear isn’t a personal failing; it’s forged by the systemic pressures we all face. Our clinical judgment feels flimsy because of:

• The fear of litigation: A “soft” diagnosis is a liability. A positive test is a shield.
• The tyranny of “test-based” medicine: The noble idea of “evidence-based” medicine has been bastardized. If a condition lacks a biomarker, we’re taught it’s less “real.”
• Pressure from gatekeepers: Insurance companies don’t do ambiguity.
• The silos of specialization: These are full-body conditions, and the patient gets bounced between us, with no one captaining the ship.

The ultimate question: Are we doing more harm?

Yes. Full stop.

When we raise the bar for diagnosis so high that only the most severe or luckiest patients can clear it, we engage in systemic medical gaslighting. We do harm by delaying treatment, inflicting diagnostic fatigue, and severing the sacred trust that is the foundation of our profession.

My job isn’t to be the expert with all the answers. It’s to sit in that uncomfortable, uncertain space with my patients. It’s to bridge our fears by saying, “I see the storm, even if the weather report says it’s sunny. Now, let’s build a better boat.”

It’s time for clinical courage. It’s time to treat the patient, not the proof.

Kara Wada is an adult and pediatric allergy, immunology, and lifestyle medicine physician.